Opinion

Video

Looking Ahead: Future Landscape for Treating OFF Time and Dyskinesia

Author(s):

Daniel E. Kremens, MD, JD

An expert discusses D1 receptor agonists that reduce negative symptoms and the increasing availability of recent and upcoming PUMP options for Parkinson disease treatment.

Related Videos
Fernando L. Pagan, MD
Fernando L. Pagan, MD
Fernando L. Pagan, MD
Fernando L. Pagan, MD
5 experts in this video
Related Content
Valbenazine Safe and Effective for Long-Term Treatment of Tardive Dyskinesia in Elders
April 29th 2025

Valbenazine Safe and Effective for Long-Term Treatment of Tardive Dyskinesia in Elders

Marco Meglio
Multisymptomatic Care in Parkinson's Disease
September 4th 2024

Multisymptomatic Care in Parkinson's Disease

Stuart H. Isaacson, MD, FAAN Rajesh Pahwa, MD Jennifer G. Goldman, MD, MS
Geko’s Transcutaneous Tibial Nerve Stimulation Fails to Improve Lower Urinary Tract Symptoms in Parkinson Disease
April 22nd 2025

Geko’s Transcutaneous Tibial Nerve Stimulation Fails to Improve Lower Urinary Tract Symptoms in Parkinson Disease

Marco Meglio
Sleeping Around the Podcast × NeurologyLive: Candidate Biomarkers to Detect REM Sleep Behavior Disorder in Parkinson Disease
April 9th 2024

Sleeping Around the Podcast × NeurologyLive: Candidate Biomarkers to Detect REM Sleep Behavior Disorder in Parkinson Disease

Anne Marie Morse, DO, FAASM NeurologyLive® Staff
Patient-Informed Phase 2 ATLANTIS Study Tests Selective D1PAM Agent Glovadalen for Parkinson Disease
April 3rd 2025

Patient-Informed Phase 2 ATLANTIS Study Tests Selective D1PAM Agent Glovadalen for Parkinson Disease

Marco Meglio
Viktoria Azoidou, PhD (Credit: Charco Neurotech)
April 3rd 2025

Vibrotactile Stimulation Device Shows Promise in Addressing Gait Issues in Parkinson Disease

Isabella Ciccone, MPH
© 2025 MJH Life Sciences

All rights reserved.